ROCO:6846's Gross Margin % is ranked worse than 62.02% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs ROCO:6846: 48.08
Greenyn Biotechnology Co had a gross margin of 48.43% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Greenyn Biotechnology Co was -1.80% per year.
Greenyn Biotechnology Co (ROCO:6846) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Greenyn Biotechnology Co had a gross margin of 48.43% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Greenyn Biotechnology Co Gross Margin % Related Terms
Greenyn Biotechnology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6846 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Greenyn Biotechnology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenyn Biotechnology Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Greenyn Biotechnology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Greenyn Biotechnology Co (ROCO:6846) has a Gross Margin % of 48.43% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Greenyn Biotechnology Co and its competitors. This is near median its historical median of 51.15. Over the past decade, Greenyn Biotechnology Co's Gross Margin % has ranged from 47.55 to 53.38. According to the industry distribution chart, Greenyn Biotechnology Co ranks #454 out of 732 companies in the Biotechnology industry, placing it in the top 62%.
Is Greenyn Biotechnology Co's Gross Margin % too high?
Greenyn Biotechnology Co's current Gross Margin % of 48.43% is near median its 10-year median of 51.15. Over the past 10 years, this metric has ranged from a low of 47.55 to a high of 53.38. The Biotechnology industry median Gross Margin % is 60.91. Greenyn Biotechnology Co's value of 48.43% is 20.5% below this industry median. Based on the distribution chart, Greenyn Biotechnology Co ranks #454 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Greenyn Biotechnology Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Greenyn Biotechnology Co ranks #454 out of 732 companies for Gross Margin %. This places Greenyn Biotechnology Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Greenyn Biotechnology Co's value of 48.43% is 20.5% below this benchmark. Historically, Greenyn Biotechnology Co's own Gross Margin % has ranged from 47.55 to 53.38 over the past decade. While the company's 10-year median is 51.15 vs. the industry median of 60.91, Greenyn Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenyn Biotechnology Co's current Gross Margin % of 48.43% is 20.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Greenyn Biotechnology Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenyn Biotechnology Co's current Gross Margin % is 48.43%, which is near median its own 10-year median of 51.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Fairly Valued. The stock's GF Value™ is NT$66.81, compared to a current price of NT$64.30 — trading 3.8% below its estimated fair value. The current Gross Margin % is 48.43%, which is near median its 10-year median of 51.15 and 20.5% below the Biotechnology industry median of 60.91. Greenyn Biotechnology Co's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current Gross Margin % is 48.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?
Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued.
The current stock price of NT$64.30 is trading 3.8% below its estimated GF Value™ of NT$66.81.
GuruFocus considers Greenyn Biotechnology Co to be Fairly Valued.
Key valuation signals for ROCO:6846:
Gross Margin %: 48.43% (near median its 10-year median of 51.15)
GF Value™: NT$66.81 vs. price of NT$64.30 (3.8% below fair value)
Industry Position: 20.5% below the Biotechnology median (#454 of 732)
No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
65GF Score
Get the complete analysis for ROCO:6846
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6846 has been successfully added to your 
